You are on page 1of 4

The First Annual Conference on Translational Biomarkers in Diagnostics ...

http://www.isbht.org/conference/conference.htm

Recommend

6

Send

Share

Purpose
The chief objective of this interactive event is to facilitate thoughtful exchanges between the key Indian stakeholders and those participating from the USA. The Institute for Strategic Biotechnology, Health & Training (ISBHT) has taken the lead in organizing the first event of this scale on this important topic in Mumbai, India. Many international leaders from academia, industry and technology will be in participation. The goals: • Showcase new merging technologies • Highlight recent success stories • Explore the utility of translational biomarkers in the healthcare settings • Deliberate opportunities for potential partnerships and collaborations with technology providers and organizations • Discuss potential licensing opportunities in novel biomarkers technologies • Assess the potential for Indian bio-repositories and their standards • Explore new business opportunities and ventures, and • Develop ideas for follow up actions

Sponsors

Like this? Let us know.

Add a comment...

Comment using...

Preamble
Post genomics, many new technologies such as proteomics, transcriptomics and metabolomics are empowering researchers to detect and monitor therapeutic interventions more readily than ever before. Biomarkers, which can now be measured by high-throughput approaches, represent the repertoire of biochemical moieties present in cells, tissues and body fluids. These molecules are the final products of interactions between gene expression, protein expression and the cellular environment. Biomarkers thus represent a state of physiology or pathology. Rapid advances in this field have been helpful to realize the development and delivery of personalized approaches to disease prevention, diagnosis and treatment much sooner than one had anticipated. Translational biomarkers are those measured in body fluids and/or tissues, and that are ready to be applied to the population to evaluate the state of physiological or pathological (disease) conditions. The application of biomarkers to the prediction, diagnosis and treatment of diseases is revolutionizing the development of disease-specific treatment strategies within the healthcare setting. Many disease-specific biomarkers are ready for their immediate use under a variety of healthcare settings. These could involve

Joseph Curtis Principal Strategic Concepts Strategic opportunity to develop commercial applications for healthcare. Predictive diagnostic platforms are the futhre.

1 of 2

9/29/2011 9:04 AM

The First Annual Conference on Translational Biomarkers in Diagnostics ...

http://www.isbht.org/conference/conference.htm

patient stratification, diagnosis and therapeutic monitoring (prognostic), and therapeutics (drugs) development based on their clinical responsiveness in individuals with different genetic/environmental susceptibilities. These single (or panels) of disease-specific biomarkers have cleared the way to use a multi-faceted approach to total patient care and to offer the ability to improve the existing approaches or develop new predictive, diagnostic and therapeutic methods. Personalized medicine offers patients and clinicians several advantages such as: a) Informed medical decisions b) Better-targeted therapies c) Reduction in potential side effects d) Prevent conditions using predictive models e) Early disease intervention using predictive molecular and imaging technologies f) Targeted drugs based on genetic susceptibility g) Effective healthcare delivery with advanced technologies h) Reduction in healthcare costs Companion Biomarkers, when successfully applied to the population, offer a number of advantages to: a) Identifying genetic predisposition to diseases (Risk Assessment) b) Developing intervention strategies to prevent behavioral/lifestyle diseases (Prevention) c) Detecting diseases early using molecular markers (Early Detection) d) Diagnosing diseases accurately and develop individualized treatment strategies (Diagnosis) e) Improving outcomes through targeted treatments and reduced side effects (Treatment) f) Monitoring treatment responses and disease progression (Management) With the increasing use of disease-specific biomarkers in healthcare settings, new regulatory requirements are evolving to clear approval processes for their use. The growth in healthcare-driven biomarkers has also resulted in many new small enterprises. This has led to the creation of repositories and standards for their use in the biomarkers validation. Further, the need for additional bio-repositories is increasing. India is well positioned to respond to this need, by populating new repositories and helping drive advances in the field of biomarkers-based healthcare.

2 of 2

9/29/2011 9:04 AM

The First Annual Conference on Translational Biomarkers in Diagnostics ...

http://www.isbht.org/conference/speakers.htm

Recommend

6

Send

Share

Speakers
Uma Prabhakar PhD
Consultant Alliance for Nanotechnology in Cancer Office of the National Cancer Institute Bethesda, MD Vice President - R&D, Healthcare & Science Thomson Reuters, Genego San Diego, CA Professor of Radiology Biochemistry & Molecular Biophysics, and Biomedical Engineering Chief, Optical Radiology Laboratory Washington University School of Medicine St. Louis, MO President & CEO CytImmune Rockville, MD LifeGen Technologies Madison, WI Director - Special Chemistry and CSO Center for Advanced Laboratory Medicine Department of Pathology and Cell Biology Columbia University Medical Center New York, NY Vice President NanoInk Skokie, IL Louise M. Williams Endowed Chair Prof, Pediatrics and Developmental Biology Director of Nephrology and Hypertension Director, Clinical Nephrology Laboratories CEO, Dialysis Unit Cincinnati Children's Hospital Medical Center University of Cincinnati College of Medicine, Cincinnati, OH Scientist - Danforth Plant Science Center Proteomics and Genomics Program Nuclear Medicine, Biomarker Imaging and Radiopharma Consultant Guidepoint Global Research Consultants, NY St. Louis, MO Professor Veterans Affairs Medical Center Karmanos Cancer Institute Departments of Internal Medicine and Pathology Wayne State University School of Medicine Detroit, MI Sellersville, PA Pulmonary and Critical Care Medicine Stanford University School of Medicine Stanford, CA New London, CT Virginia, USA

Sponsors

Yuri Nikolsky PhD, MBA

Samuel Achilefu PhD

Lawrence Tamarkin PhD Jamie Barger

Like this? Let us know.
Add a comment...

Alex J. Rai PhD, DABCC, FACB

Comment using...

Haris Jamil PhD

Joseph Curtis Principal Strategic Concepts Strategic opportunity to develop commercial applications for healthcare. Predictive diagnostic platforms are the futhre. Reply Like September 17 at 7:36pm
Facebook social plugin

Prasad Devarajan MD

Raghu Pandurangi PhD

Adhip P. N. Majumdar PhD

Kamala Kalyani Maddali DVM, PhD Daya Upadhyay MD Manoj Rajadhyaksha PhD Peter Barker PhD

1 of 2

9/29/2011 8:45 AM

The First Annual Conference on Translational Biomarkers in Diagnostics ...

http://www.isbht.org/conference/speakers.htm

Pushpa Tandon PhD

Program Director Cancer Imaging Program Image Guided Interventions Branch National Cancer Institute Bethesda, MD Distinguished Scientist Senior Principal Investigator Carestream Health Woodbridge, CT Tata Memorial Hospital Mumbai, India Scientist E- II Developmental Toxicology Division Indian Institute of Toxicology Research M.G. Marg, Lucknow 226 001 India Department of Biochemistry University of Puerto Rico Puerto Rico, USA Department of Regenerative Medicine Medical University of South Carolina Charleston, SC Assistant Professor Center for Molecular Imaging University of Texas Houston, TX Professor of Dermatology Health Sciences and Technology Harvard Medical School Director, Office for Research Career Development Massachusetts General Hospital Wellman Center for Photomedicine 40 Fruit Street, BAR 314 Boston, MA 02114 Scientist F & Head, Developmental Toxicology Division Indian Institute of Toxicology Research P.O. Box 80, M.G. Marg Lucknow 226 001 India

Rao V.L. Papineni PhD

Pankaj Chaturvedi MD

Alok Dhawan PhD, FST, MNASc, MAMS

Dipak Banerjee PhD

Suniti Misra PhD

Ali Azhdarinia PhD

Tayyaba Hasan PhD

Devendra Parmar PhD

2 of 2

9/29/2011 8:45 AM